BioSpace News Archive

Further expands Company’s patent portfolio in pursuit of worldwide intellectual property protection for Primer-Switch technology; Applicable to Coronavirus (COVID-19) Molecular Diagnostic Testing

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program, in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD), during the 25 th International Congress of the World Muscle Society

Baxter Announces U.S. FDA Approval of Clinimix and Clinimix E with Higher Protein for Patients Requiring Parenteral Nutrition New formulations provide up to 60% more protein (amino acid) than current Clinimix formulations while delivering less dextrose 1

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operating at the

Beginning this week, plasma from whole blood and platelet donations made through the American Red Cross that test positive for COVID-19 antibodies may now help coronavirus patients in need of convalescent plasma transfusions.

Nutcracker Therapeutics, Inc., a company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, today announced the appointment of Madhavan (“Madhu”) Balachandran, former executive vice president of operations at Amgen, as chief operating officer. Balachandran will oversee all op

Whether children have returned to in-school classrooms, are learning remotely at home, or are doing a combination of both, the 2020-2021 school year promises to be a constantly changing and challenging experience during the ongoing pandemic.

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the launch of its “Forward for Health Equity” grant program.

Centene Corporation announced that it has commenced an underwritten public offering to sell $2,200,000,000 of senior notes due 2030, subject to market and other conditions.

Metabolon, Inc., the global leader in metabolomics solutions advancing drug development and precision medicine, today announced the close on $72 million in combined debt and equity financing.